Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Liuying Township, Taiwan Clinical Trials

A listing of Liuying Township, Taiwan clinical trials actively recruiting patients volunteers.

RESULTS

Found (1946) clinical trials

The study will determine Recommended Phase 2 Dose for all study drugs, based on the safety and tolerability of the following combinations: INCAGN02385 + INCAGN02390 and INCAGN02385 + INCAGN02390 + INCMGA00012.  

Phase

Phase 1/1b to establish the maximum tolerated dose of the combination of study drugs in patients with advanced solid tumor malignancies with a KRAS G12C mutation. Phase 2 to evaluate clinical activity of the combination of study drugs in selected solid tumor malignancies with KRAS G12C mutation.  

Phase

The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies in subjects with advanced or metastatic malignancies.  

Phase

Evaluates the safety, tolerability, pharmacokinetics, metabolites, pharmacodynamics, and clinical activity of MRTX849 in patients with advanced solid tumors with a KRAS G12C mutation. MRTX849 is an orally-available small molecule inhibitor of KRAS G12C.  

Phase

This is an open-label, multicenter, Phase 1b platform study in subjects with advanced or metastatic solid tumors (Part 1a) and subjects with selected solid tumors (Part 1b and Part 2). Two treatment groups (Group A and Group B) will be evaluated. Part 1a utilizes a 3+3 design to evaluate pembrolizumab …

Phase

Tolerability Efficacy and PK of ZSP1601 in Patients With Non-Alcoholic Steatohepatitis (NASH)

Double-blind, randomized, placebo-controlled study to explore the safety, tolerability PK characteristics and early efficacy of ZSP1601 tablets in patients with non-alcoholic steatohepatitis (NASH).

Phase

A Study of LY2880070 in Participants With Advanced or Metastatic Cancer

The main purpose of this two-part study is to evaluate the safety and efficacy of the study drug known as LY2880070 in participants with advanced or metastatic solid tumors.

Phase

Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors

This study is an open-label Phase 1 evaluation of INCB001158 as a single agent and in combination with immune checkpoint therapy in patients with advanced/metastatic solid tumors. Single Agent INCB001158: Patients with advanced/metastatic solid tumors will be enrolled into escalating monotherapy dose cohorts to determine the Recommended Phase 2 Dose …

Phase

Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma

The primary objectives of this study are: Phase 1: To evaluate the safety of sequenced therapy with lenzilumab and axicabtagene ciloleucel in participants with relapsed or refractory large B-cell lymphoma and identify the most appropriate dose of lenzilumab for Phase 2. Phase 2: To evaluate the incidence of neurologic events …

Phase

Quantitating the Impact of Plerixafor

The investigators have previously demonstrated that proteasome inhibition (with bortezomib) provides effective antihumoral therapy for antibody-mediated rejection (AMR) and for desensitization in kidney transplant recipients and candidates. These studies have also demonstrated that plasma cell populations exhibit significant heterogeneity. Newly produced plasma blasts and plasma cells, whether from a primary …

Phase